RARB
Retinoic acid receptor beta
As of the edition of 20 October 2026, RARB (retinoic acid receptor beta, UniProt P10826) has 9 drugs tested at it and 17 companies on the list, 0 on route A and 6 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P10826
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 9
- Disease areas
- Cancer; Skin and connective tissue; Blood and lymph; Immune system; Urinary and reproductive; Infections; Lungs and airways; Digestive system
- Registered trials of its drugs
- 425
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 6 |
| Stopped | 1 |
| Withdrawn from market | 1 |
| Status not established | 1 |
| Total | 9 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tretinoin | Marketed | Phase 4 | none listed |
| Isotretinoin | Marketed | Phase 4 | none listed |
| Adapalene | Marketed | Phase 4 | none listed |
| Tazarotene | Marketed | Phase 4 | none listed |
| Acitretin | Marketed | Phase 4 | none listed |
| Alitretinoin | Marketed | Phase 3 | none listed |
| Tamibarotene | Stopped | Phase 3 | none listed |
| TMB-001 | Status not established | Phase 3 | none listed |
| Etretinate | Withdrawn from market | No phase stated | none listed |
9 of 9 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 6 |
| Engaged | 6 |
| Undetermined | 5 |
| Total on the list | 17 |
The other 14 companies at RARB
In the product17 companies in all; 14 are not named here, and no score is.
See the 17 companies at RARB, ranked, with the facts behind eachRequest access. Nothing is shown until you do.